We are an emerging global pharmaceutical company focused on identifying, developing, and upon approval, commercializing existing approved drugs and drug candidates for new indications. Our focus is on delivering effective, evidence-based treatments to manage less common diseases.
Company profile
Ticker
ASPV
Exchange
Website
CEO
Andrew M. Rooke
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
980435540
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
31 Jan 12
CT ORDER
Confidential treatment order
31 Jan 12
15-12G
Securities registration termination
11 Jan 08
8-K
Aspreva’s Plan of Arrangement with Galenica Completed
8 Jan 08
25-NSE
Exchange delisting
3 Jan 08
8-K
Aspreva Receives Investment Canada Approval for Acquisition by Galenica
24 Dec 07
8-K
Entry into a Material Definitive Agreement
20 Dec 07
8-K
Aspreva Receives Final Court Approval for Acquisition by Galenica
19 Dec 07
8-K
Aspreva Obtains Shareholder Approval for Acquisition by Galenica
17 Dec 07
8-K
Other Events
23 Nov 07
Latest ownership filings
No filings